Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ardea Biosciences, Inc.
The study will assess the BE between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fed state.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Subject has a body mass index ranging between 18 kg/m2 and 30 kg/m2.
Screening serum urate level is ≤ 7.0 mg/dL.
You may not be if
Asian subject who has a positive test for the HLA-B\*5801 allele.
History or suspicion of kidney stones.
Estimated creatinine clearance, as determined at Screening, of \< 90 mL/min calculated by the Cockcroft-Gault formula using ideal body weight.
Undergone major surgery within 3 months prior to Screening.
Donated blood or experienced significant blood loss (\> 450 mL) within 12 weeks prior to Day 1or has given a plasma donation within 4 weeks prior to Day 1.
Inadequate venous access or unsuitable veins for repeated venipuncture.
Received any strong or moderate enzyme-inducing drug or product within 2 months prior to Screening
Clareo Health | Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence
